معرفی
Wim Versées is a Staff Scientist at the Flanders Institute for Biotechnology (VIB), affiliated with the Department of Bio-engineering Sciences at Vrije Universiteit Brussel (VUB). He also held a postdoctoral position at the Max Planck Institute of Molecular Physiology. His research focuses on structural biology, enzymology, and biophysics, particularly investigating enzymes linked to human diseases like Parkinson’s and epilepsy. His group studies GTPase proteins, such as LRRK2 and ObgE, to develop therapeutic strategies.
He leads projects on nanobody-based therapies, protein structure determination, and enzymatic mechanisms. Notable achievements include the discovery of nanobodies modulating LRRK2 activity and structural insights into β-glucocerebrosidase. He received the 2022 Wetenschappelijk Fonds Willy Gepts award for SPARTAN research on Parkinson’s therapies.
- Education: Advanced training in structural biology and enzymology.
Research interests span enzyme kinetics, GTPase networks, and translational medicine. Recent work highlights nanobodies as molecular chaperones and inhibitors of disease-associated enzymes. His lab collaborates globally, leveraging cryo-EM and bioinformatics for structural studies.
Grants include funding for high-resolution microscopy and protein interaction studies. He advises PhD students, including Babette Deckers and Christian Galicia, and publishes widely in Nature Communications and eLife. Media highlights include breakthroughs in Parkinson’s treatment via llama antibodies.
Key labs/teams: VIB Structural Biology group, collaborations with institutions like the Max Planck Institute and VUB.
